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Abstract: Neuromuscular diseases (NMDs) are a heterogeneous group of acquired or inherited rare
disorders caused by injury or dysfunction of the anterior horn cells of the spinal cord (lower motor
neurons), peripheral nerves, neuromuscular junctions, or skeletal muscles leading to muscle weakness
and waste. Unfortunately, most of them entail serious or even fatal consequences. The prevalence
rates among NMDs range between 1 and 10 per 100,000 population, but their rarity and diversity
pose difficulties for healthcare and research. Some molecular hallmarks are being explored to
elucidate the mechanisms triggering disease, to set the path for further advances. In fact, in the
present review we outline the metabolic alterations of NMDs, mainly focusing on the role of
mitochondria. The aim of the review is to discuss the mechanisms underlying energy production,
oxidative stress generation, cell signaling, autophagy, and inflammation triggered or conditioned
by the mitochondria. Briefly, increased levels of inflammation have been linked to reactive oxygen
species (ROS) accumulation, which is key in mitochondrial genomic instability and mitochondrial
respiratory chain (MRC) dysfunction. ROS burst, impaired autophagy, and increased inflammation
are observed in many NMDs. Increasing knowledge of the etiology of NMDs will help to develop
better diagnosis and treatments, eventually reducing the health and economic burden of NMDs for
patients and healthcare systems.
Keywords: neuromuscular diseases (NMDs); mitophagy; reactive oxygen species (ROS);
damage-associated molecular patterns (DAMPs); oxidative stress; mitochondrial respiratory
chain (MRC)
1. Introduction
1.1. Neuromuscular Diseases (NMDs)
NMDs are a heterogeneous group of acquired or inherited rare disorders caused by injury
or dysfunction of the anterior horn cells of the spinal cord (lower motor neurons), peripheral
nerves, neuromuscular junctions (NMJ), or skeletal muscles, resulting in muscle weakness and waste,
swallowing and breathing difficulties, and cardiac failure [1]. NMDs share some common features:
weakness, twitching, torpidity, and cramps but signs and symptoms of various NMDs might be very
different [2]. Unfortunately, most of them entail serious or even fatal consequences.
NMDs exhibit a diversity of symptoms due to large genetic and clinical heterogeneity, as more
than 500 genes are implicated in their pathogenesis, setting difficulties for healthcare and research [2,3].
Most NMDs’ prevalence ranges between 1 and 10 per 100,000 population [4]. Given the rarity and
diversity of NMDs, patients experience long delays in diagnosis (typically 7 years) and 30% are never
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achieved [1], probably because many of them lack non-invasive diagnostic and prognostic biomarkers.
Likewise, models of disease or therapeutic options are infrequent, but growing interests and knowledge
are focused in depicting the etiology of these disorders [5].
Currently, diagnosing NMD starts with clinical observation, which can identify atrophy or loss of
muscle bulk or tone. Blood tests can determine abnormal levels of various common metabolites and
antigens in certain NMD. In addition, electromyography (EMG) helps to assess the health of muscles
and lower motor neuron nerve cells that control those muscles to diagnose a number of NMD [6].
Once muscle affection is assured, multitude of diagnostic algorithms are developed to establish the
specific disorder. Usually, muscle biopsy takes part in the diagnostic clues. Depending on the clinical
and pathological presentation, the study of mitochondrial DNA (mtDNA) genome and mitochondrial
respiratory chain (MRC) function is also required [7]. This fact indicates the mitochondrial etiology of
some NMDs and why mitochondrial deregulation may play a role in the rest.
Despite the challenges in NMD diagnosis, genetic diagnosis of these diseases has improved over
the last 20 years [8]. Advances in sequencing and understanding the human genome has helped to
detect monogenic NMD. Improved diagnosis and increased life expectancy may rise the prevalence of
NMD worldwide while massive genome sequencing helps to depict complex disease inheritance and
etiology. In addition, research in pathways affected in NMD is essential to improve the treatments and
guide toward more personalized therapies in NMDs.
Classification of NMDs
The knowledge about new NMDs is continually increasing and changing. Currently, there are 7
main groups of NMDs, represented in Figure 1, which are [6,9,10]:
• Muscular dystrophies (MD): affect the structure of the muscle cells, causing weakness and
degeneration of the skeletal muscles. MD subtypes are described in Table 1.
• Myopathies other than dystrophies: affect tone and contraction of muscles controlling voluntary
movements; may include inflammation of muscles or related tissues, resulting in muscular
weakness. Numerous myopathies have been described and classified in different groups (Table 2).
• Neuromuscular junction (NMJ) diseases: result from the destruction, dysfunction, or absence of
one or more key proteins involved in the transmission of signals between nerves and muscles
(Table 3).
• Motor neuron diseases: involve nerve cells in the spinal cord (lower motor neurons). Lower motor
neurons progressively lose their function, causing the muscles they control to become weak and
eventually non-functional (Table 3).
• Peripheral nerve diseases: involve motor and sensory nerves that connect the brain and spinal
cord to the rest of the body causing impaired sensations, movement or other functions (Table 4).
• Mitochondrial diseases: involve errors in metabolism that affect energy production in muscle cells
(Table 4).
• Ion channel diseases: diseases associated with defects in proteins forming ion channels, leading to
muscular weakness, absent muscle tone, or episodic muscle paralysis (Table 5).
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Figure 1. Representation of a motor unit according to the classification of the main neuromuscular 
diseases (NMDs). Muscle cells and neurons interact in the neuromuscular junction (NMJ) where 
muscle cells receive the instructions from the lower motor neurons to perform the actions required. 
Thus, body movement is actioned by muscle fibers but controlled by the nervous system. 
Consequently, alterations in muscle fibers or nerves can both trigger a NMD. Figure created with 
BioRender.com. 
 
Figure 1. Representation of a motor unit according to the classification of the main neuromuscular
diseases (NMD ). Muscle cells and ne rons interact in the neuromuscular junction (NMJ) where m scle
cells receive the instru tions from the lower motor neurons to perform the actions required. Thus,
body movement is actio ed by muscle fibers but contr lled by the nervous system. Cons ently,
alterations in muscle fiber or nerv s can both trigger a NMD. Figu e created with BioRender.com.
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Table 1. Examples of studies reporting altered mitochondrial functions in muscular dystrophies.
NMD Group Name of MainDiseases
Description of Principal Disease
Features















Becker MD (BMD) Atrophy of the skeletal, cardiac,and pulmonary muscles
Reduced mitochondrial mass, complex I





in vitro, cells, animal




Muscle weakness and possible joint
deformities with slow progression
and shortened life span
Most common CMD are collagen VI





in vitro, cells, animal
(Col6a1 -/- mice),
patient (CT)
[2,14,15] LMNA, DPM3,DAG1, TRAPPC11
Duchenne MD (DMD)
General muscle weakness and
wasting due to lack of dystrophin
protein. Shortened lifespan. Rarely
affects women (milder symptoms
and better prognosis)
Massive aggregates of mitochondria,
lower activities of MRC complexes III




in vitro, cells, animal





Muscular weakness and atrophy of
shoulder, upper arm, and shin
muscles, with early joint
contractures and cardiomyopathy
Reduced expression of MRC complex
genes and upregulation of mitochondrial
disassembly genes, altered



















cells and patient (CT) [14,17,25,26] TRPV4, DUX4,SMCHD1
Limb-girdle MD
(LGMD)
Weakness and wasting of the
muscles in hips and shoulders
Morphologic mitochondrial














Muscle loss and weakness due to
inability to relax them. It affects
facial muscles first, but also feet,
hands, and neck
Altered mitochondrial proteins
(decreased EF-Tu, hsp60, GRP75, dienoyl
CoA isomerase) and disruption of





cells and patient (CT) [14,28,29] CNBP (ZNF9),DMPK
Oculopha-ryngeal MD
(OPMD)
Weakness of eye, face, and throat
muscles leading to drooping
eyelids and problems with
swallowing
PABPN1 protein aggregates, reduced
complex I and V mitochondrial proteins,





in vitro, cells, animal,
patient (CT) [24,30–32] PABPN1
Distal MD (DD) (or
Distal myopathy)
Weakness and wasting of muscles
of the hands, forearms, and lower




oxygen consumption and Ca2+ and
deficiencies in MRC complexes I and IV
MPTP opening and
ATP depletion
in vitro, cells, patient
(CT) [14,33,34] FLNC, TTN, DYSF
Family of muscular dystrophies (MD) and their respective disease features, mitochondrial alterations, affected mitochondrial pathways, evidence level of altered mechanisms, mutations
in causal genes and relevant references. Examples of genes with mutations causal/related to a MD taken from Muscle gene table (accessed July 2020) [35]. * More LGMD mutations:
HNRNPDL, CAPN3, COL6A1, SGCA, SGCB, SGCG, SGCD, POMT1, POMT2, POMGNT1, POMGNT2, FKTN, ANO5, COL6A2, COL6A3, DAG1, PLEC, TRAPPC11, GMPPB, ISPD,
POGLUT1, DNAJB6, FKRP, TTN, LAMA2, BVES. Abbreviations: MPTP: mitochondrial permeability transition pore; ROS: reactive oxygen species; CT: clinical trials; RRF: ragged-red fibers;
COX: cytochrome c oxidase, MRC complex IV; ER: endoplasmic reticulum; UPR: unfolded protein response.
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Table 2. Examples of studies reporting altered mitochondrial functions in myopathies other than dystrophies.
NMD Group Name of MainDiseases
Description of Principal Disease
Features














Inherited diseases that affect the
tone and contraction of skeletal
muscles causing general muscle
weakness
The most frequent congenital
myopathies are core myopathies, with














Weakness and atrophy (shrinking)
of the muscles around the
shoulders and hips, muscle
stiffness, cramps, and slowed
reflexes caused by abnormal
activity of the thyroid gland. Two
types: hypothyroid (reduced
hormone levels) and hyperthyroid
myopathies (excess in hormones)
Hypothyroid myopathy: decreased
TFAM, reduced mitochondrial DNA
copy number and mitochondrial
alterations (COX- fibers). Hyperthyroid:










accompanied by prolonged muscle
fatigue and weakness. sIBM is the
inflammatory myopathy with more
mitochondrial alteration
Abnormal mitochondria in sIBM (RRFs
and COX- fibers). In sIBM and PM,











Group of disorders caused each by
a different genetic defect that
impairs the body’s metabolism
causing muscle weakness, exercise
intolerance, muscle pain or cramps
Altered MRC: substrates are not properly
processed or cannot enter mitochondria
affecting energy production of the cell.
mtDNA or nDNA mutations
reduced MRC and
ATP depletion







Characterized by muscle weakness,
cardiomyopathy, myalgia, loss of
sensation and weakness in the
limbs (peripheral neuropathy), and
respiratory failure
Mitochondrial abnormalities with RRF
and enlarged mitochondria. Protein
aggregates affecting distribution and
function of mitochondria. Deficiencies in













Rare genetic disorder characterized
by weakness and wasting of
specific muscles: shoulder blade
area (scapula) and the smaller of
the two leg muscle groups below
the knee (peroneal)
mtDNA mutations reported in a few
cases mtDNA cells [47–49] VCP, FHL1
Family of myopathies other than dystrophies and their respective disease features, mitochondrial alterations, affected mitochondrial pathways, evidence level of altered mechanisms,
mutations in causal genes and relevant references. Examples of genes with mutations causal/related to a myopathy taken from muscle gene table (accessed July 2020) [35]. Abbreviations:
MRC: mitochondrial respiratory chain; CT: clinical trials; TFAM: mitochondrial transcription factor A; COX-: cytochrome c oxidase negative fibers; ER: endoplasmic reticulum; sIBM:
sporadic Inclusion Body Myositis; RRF: ragged-red fibers; PM: polymyositis; mtDNA: mitochondrial DNA; nDNA: nuclear DNA.
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Table 3. Examples of studies reporting altered mitochondrial functions in Neuromuscular Junction Diseases (NMJ) and Motor Neuron Diseases.
NMD Group Name of MainDiseases
Description of Principal Disease
Features














Weakness and fatigue resulting
from problems at NMJ. Different
types of CMS, according to the part
of the NMJ affected: presynaptic
(the nerve cell), postsynaptic (the
muscle cell) or synaptic (the space
in between)
Gene defect in mitochondrial citrate
carrier SLC25A1 underlie deficits in NMJ
transmission. SLC25A1 is involved in
many biological processes (e.g.,
glycolysis, autophagy)
NMJ signaling

















Autoimmune disease that attacks
the calcium channels in the NMJ
and interferes with the ability of
nerve cells to send acetylcholine to
muscle cells, affecting muscle
contraction and causing muscle
weakness
Altered calcium channels NMJ signaling cells, patient (CT) [50,54–56] SYT2
Myasthenia gravis
(MG)
Chronic autoimmune disorder in
which antibodies destroy
neuromuscular connections. It
affects voluntary muscles of the









mice), patient (CT) [55,57,58] CHAT
Amyotrophic lateral
sclerosis (ALS)
Fatal disease with degeneration of
nerve cells in the spinal cord and
brain. It affects voluntary control of
arms and legs and eventually leads
to trouble breathing
Accumulation of mitochondrial in
proximal axons, mitochondrial injury by



















Genetic disorder in which loss of
lower motor neurons affect
voluntary muscle movement,
specifically facial, swallowing
muscles and limbs. Only affects
men
Reduced MMP. Increased expression of
apoptotic proteins that activate
mitochondrial caspase pathway. AR







in vitro, cells, animal,
patient (CT) [66–70] AR
Spinal muscular
atrophy (SMA)
Genetic disease affecting the central
and peripheral nervous system,
and voluntary muscle movement,
mainly shoulders, hips, thighs, and
upper back
Decreased enzyme activities involving














Family of neuromuscular junction diseases (NMJ) and motor neuron diseases and their respective disease features, mitochondrial alterations, affected mitochondrial pathways, evidence
level of altered mechanisms, mutations in causal genes and relevant references. Example of genes with mutations causal/related to a NMJ diseases taken from muscle gene table (accessed
July 2020) [35]. * More ALS mutations: ubiquilin 2, C9orf72, SIGMAR1, CHCHD10, C9orf72, VCP, TDP-43, SETX, FUS, VAPB. Abbreviations: NMJ: neuromuscular junction; CT: clinical
trials; RRF: ragged-red fibers; ROS: reactive oxygen species; COX I: cytochrome c oxidase subunit I; mtDNA: mitochondrial DNA; MMP: mitochondrial membrane potential; AR: androgen
receptor; MPTP: mitochondrial permeability transition pore; ER: endoplasmic reticulum.
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Table 4. Examples of studies reporting altered mitochondrial functions in peripheral nerve diseases and mitochondrial diseases.
NMD Group Name of MainDiseases
Description of Principal Disease
Features
















Inherited disorder that affects
nerves outside of your brain and
spinal cord, nerves that supply feet,
legs, hands, and arms. Two
subtypes: CMT1 (demyelinating),
CMT2 (axonal)
Altered mitochondrial dynamics and
axonal transport of mitochondria,
causing axonal degeneration. Mutations


















by abnormally large and
dysfunctional axons. First, limbs
have problems with walking,
followed by difficulties
coordinating movements (ataxia),
and require wheelchair assistance
Abnormal and enlarged mitochondria in
Schwann cells, deficiencies of complexes
I and IV, several mtDNA point mutations






in vitro, cells, animal,





Genetic defects that affect
mitochondria can cause muscular
and neurological problems (e.g.,
muscle weakness, exercise




Mutations in mtDNA or nDNA affecting
proteins involved in MRC, mitochondrial

















Muscle weakness and ataxia, loss of
balance and coordination due to
reduced synthesis of the
mitochondrial protein frataxin. It
mostly affects the spinal cord,
peripheral nerves and cerebellum
Altered synthesis of frataxin affects
mitochondrial iron metabolism and




in vitro, cells, patient
(CT) [7,80,81] FXN
Family of peripheral nerve diseases and mitochondrial diseases and their respective disease features, mitochondrial alterations, affected mitochondrial pathways, evidence level of altered
mechanisms, mutations in causal genes and relevant references. Example of genes with mutations causal/related to a peripheral nerve disease or mitochondrial disease taken from muscle
gene table (accessed July 2020) [35]. Abbreviations: ER: endoplasmic reticulum; CT: clinical trials; mtDNA: mitochondrial DNA; MRC: mitochondrial respiratory chain; nDNA: nuclear
DNA; RRF: ragged-red fibers; UPR: unfolded protein response.
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Table 5. Examples of studies reporting altered mitochondrial functions in ion channel diseases.
NMD Group Name of MainDiseases
Description of Principal Disease
Features

















Altered potassium channel gene
affect the heartbeat and the ability
of muscles to stay ready to contract.
Paralysis may occur
Mitochondrial channelopathies affect the
K+, Ca2+, VDAC and MPTP channels.
Reduced channel activity rate results in




metabolism, and modulation of cell




in vitro, cells, animal






Genetic alterations in sodium
channels results in temporary






Genetic defects in calcium or
sodium channel cause a loss of






Disease caused by mutations in the
gene encoding a chloride channel
necessary for stopping muscle
contraction. Delayed muscle





Mutations in the muscle sodium
channel gene prolong the channel’s
opening, higher muscle excitation
triggering episodes of muscle
stiffness and weakness, mostly in





Sustained muscle tensing causes
muscle stiffness that worsens after
exercise and may be aggravated by
eating potassium-rich foods
SCN4A
Family of ion channel diseases and their respective disease features, mitochondrial alterations, affected mitochondrial pathways, evidence level of altered mechanisms, mutations in causal
genes and relevant references. Example of genes with mutations causal/related to an ion channel disease taken from muscle gene table (accessed July 2020) [35]. Abbreviations: VDAC:
voltage-dependent anion channels; MPTP: mitochondrial permeability transition pore; MMP: mitochondrial membrane potential.
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1.2. Muscle and Nerve System
As outlined in the classification of NMDs, either muscle or nerve dysfunction can result in a NMD.
Both tissues are formed by highly specialized cells; neurons in the peripheral nervous system and
muscle cells (organized into sarcomeres) in skeletal muscles. Although nerve and muscle tissues contain
a reservoir of stem cells for tissue remodeling and regeneration (called satellite cells in muscles), the rate
of cell and tissue renewal is quite low, and neurons and sarcomeres, once formed, never proliferate.
This is one of the features that causes nerve and muscle tissue disease in case of cell injury.
One of the reasons for cell injury is the strong dependence that nerve and muscle tissue
have on mitochondrial function. Their high energetic needs are almost entirely sustained by
oxidative metabolism (high-energy demands provided by mitochondrial oxidative respiration). Thus,
any deficiency at mitochondrial level may endanger cell and tissue function, being the base of NMDs.
At structural level, the interaction of nervous and musculoskeletal system occurs in the NMJ,
also called motor end plate [54]. Muscles are organized in bundles, called muscle fibers, made up
of myocytes (muscle cells). Muscle fibers together with lower motor neurons form the motor unit.
To reach motor units, nerve impulses travel from the central nervous system (CNS) to the spinal cord
and to the whole body within peripheral nerves [86]. In Figure 1, a motor unit is represented together
with the classification of the main NMDs.
Muscle fibers are innervated with motor neuron axon terminals. The communication of muscle
cells with lower motor neurons is mainly based in changes in the membrane potential and ion channel
opening and closing. Briefly, when lower motor neurons are stimulated, their membrane potential
changes due to exchange of sodium (Na+) and potassium (K+) across the cell membrane, prompting
the depolarization of the neuron. Inside the neuron, Na+ entrance through specific channels promotes
the release of calcium (Ca2+) ions from the endoplasmic reticulum (ER) into the cytosol, triggering
the further release of neurotransmitters out of nerve cells. These neurotransmitters are sensed by
muscle cells, promoting the contraction of muscle fibers [87]. Muscle contraction is mainly controlled
by Ca2+ fluxes.
Ca2+ increase in the cytosol of muscle cells allows actin and myosin (contractile proteins),
to interact, causing muscle contraction. Right after, Ca2+ are pumped back into the ER causing muscle
relaxation [87]. Overall, body movement is actioned by muscle fibers controlled by the nervous system.
Energetic supply is essential for ion exchange and NMJ functioning. Based on energetic criteria
and mitochondrial metabolism, muscle fibers can be divided into two categories: type I (slow-twitch)
fibers and type II (fast-twitch) fibers. Type I fibers contain more mitochondria and myoglobin than
type II fibers. Mitochondria generate ATP by cellular respiration, for which oxygen is required and
provided by myoglobin, which stores and carries oxygen in muscle cells. Type II fibers synthesize the
majority of their energy through anaerobic respiration, without the need of oxygen, a faster process
than mitochondrial respiration but that provides lower amount of ATP [88].
Overall, the CNS and muscle require high amount of energy, mostly produced in mitochondria,
and that is why mitochondrial defects are causal or remarkable in the development of NMDs [14].
As mitochondria are essential in nerve and muscle tissue function, primary mitochondrial diseases,
caused by mutations in a mitochondrial gene, generally manifest as encephalomyopathies [89], mainly
affecting brain and muscle tissues. This is the case of mitochondrial encephalomyopathy with lactic
acidosis syndrome (MELAS) or myoclonic epilepsy with ragged-red fibers (MERRF). NMD such
as Charcot-Marie-Tooth neuropathy type 2A (CMT2A) [74] or amyotrophic lateral sclerosis (ALS)
can also be caused by mitochondrial mutations (CMT2A can be caused by mutations in MFN2
and ALS by mutations in SOD1) [59]. Interestingly, mitochondria can also play a secondary role
in the development of the rest of NMD when the mutation or deficiency is not directly related or
located in the mitochondria, since affected cells will need additional ATP to support homeostatic
mechanisms disbalanced (anti-stress or antioxidant responses), while minimizing the production
of ROS. If mitochondria are unable to counterbalance cell dysfunction, a secondary mitochondrial
disease will appear, like spinal muscular atrophy (SMA) (usually caused by a mutation in SMN1) [71]
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or Duchenne muscular dystrophy (DMD) due to mutation in DMD) [90]. Therefore, mitochondrial
function is key in the onset or progression of most of NMDs, regardless of their genetic origin.
1.3. Mitochondrial Function
Despite their clinical and pathological diversity, some overlaps can arise among all NMDs. One of
them are molecular events revealing metabolic alterations related to the mitochondria. Although
originally considered the “powerhouse of the cell” [91], mitochondria are organelles with a central role
in multiple cellular processes: ATP production, apoptosis, β-oxidation of fatty acids, iron-sulfur cluster
synthesis and in a broader range of signaling pathways. Additionally, in case of troubleshooting,
mitochondria are the main center of ROS production and cell death through the control of apoptosis [92].
Thus, mitochondrial health is essential for cell function and any misbalance in bioenergetics can
endanger cell, tissue, and patient survival [93].
Mitochondria can multiply their number in case of energy need or survival of cells, through
a process called mitochondrial biogenesis [94]. In addition, mitochondria are dynamic organelles
that constantly fuse and divide to increase their energy supply (fusion) or target the mitochondria
for degradation (fission). This process is called mitochondrial dynamics and triggers changes in
mitochondrial number, morphology, and size [92].
Even if the number of mitochondria rises in a cell, impairment of MRC increases the production of
ROS [95], which increases the oxidative stress levels in cells, activating mechanisms to counterbalance
this excessive ROS. These repair mechanisms start with autophagy and mitophagy. Autophagy is the
clearance of damaged organelles and protein aggregates by lysosomal degradation; while mitophagy
is a specialized autophagy that degrades dysfunctional mitochondria to maintain mitochondrial
integrity [96]. Both processes remove the excess of ROS produced in mitochondria. Excessive ROS can
also affect the ER, as it is one of the main sensors of cellular stress. ER and mitochondria are connected
through mitochondria-ER membrane contact sites, called mitochondria-associated membranes (MAMs).
When ER senses ROS, ER redox status can change, and might induce ER stress [97]. To defend against
ER stress and overcome potential protein misfolding, cells can activate an adaptive unfolded protein
response (UPR), which increases the size and capacity of ER to reduce ER stress and increase the
removal of misfolded proteins by autophagy [98].
In addition, excessive ROS can trigger an intracellular inflammatory response [99] which has
an impact in mitochondrial genomic instability and respiratory chain dysfunction [100]. ROS burst,
impaired autophagy, and increased inflammation are observed in many NMDs [101], whose prevalence
increases with aging. However, these mechanisms have not been thoroughly revised in all groups of
NMD and have not been compared before.
Overall, the aim of this review is to point out the role of excessive oxidative stress in mitochondrial
function and its impact in autophagy and inflammation in NMDs (Tables 1–5). Increasing knowledge
of the etiology of NMDs will help to develop better diagnosis and treatments to modify the natural
history of these chronic disabling diseases, eventually reducing both health and economic burdens of
NMDs for patients and healthcare systems [9].
2. Mitochondrial Pathways Altered in NMD
2.1. Mitochondrial Genome and mtDNA Mutations
Mitochondria contain their own genome, which encodes 13 proteins, 22 tRNAs, and 2 rRNAs.
The remaining proteins involved in mitochondrial structure and function are encoded by the nuclear
DNA, translated in the cytosol and translocated into mitochondria [92]. Although mtDNA only encodes
±1% of the mitochondrial proteins, these elements are critical components of the MRC, essential for
mitochondrial function [94]. Nuclear and mitochondrial intergenomic communication is essential to
build the MRC complexes that enables cell bioenergetics and promotes healthy organ function [102].
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If mtDNA mutates, these mutations can be present in all mtDNA copies in the cell (homoplasmy)
or only in a fraction (heteroplasmy). Almost all humans carry low levels of heteroplasmic mtDNA
point mutations, which could be pathogenic [103]. Both the subcellular distribution of mutated mtDNA
and the intrinsic pathogenicity of the mutation itself may also be important in determining whether a
mtDNA defect is expressed phenotypically [7]. mtDNA mutations are also related to the aging process
or age-associated diseases [94].
The distribution of a mutation in different tissues may change with time depending on the mitotic
activity of the tissue [92]. In tissues with ongoing cell division, there is a chance that a defect in mtDNA
may be selected in or out. This may explain the predilection for mitochondrial diseases to manifest
clinically in postmitotic tissues such as the central nervous system and skeletal muscle. This mechanism
may also explain why some mitochondrial phenotypes change with time [7,104].
Pathogenic mtDNA mutations must be present in 60–90% of mitochondria in a cell to trigger
MRC dysfunction [105]. Computational models estimate that only mtDNA mutations generated in
early life could expand to reach the threshold and cause MRC dysfunction in aging human adults [106].
One of the reasons is because mtDNA is organized into mitochondrial nucleoids [107] and coupled
with mitochondrial transcription factor A (TFAM), to make mtDNA less accessible to mutations than
naked DNA. In fact, lower amount of TFAM is found in hypothyroid myopathy (endocrine myopathy,
Table 2), triggering reduced mtDNA copy number and mitochondrial dysfunction [38].
Other NMDs associated to mtDNA mutations are metabolic myopathies, ALS, CMT2,
mitochondrial myopathies, and Friedreich’s ataxia (Tables 2–4).
Apart from mtDNA point mutations, single large deletion in mtDNA at high levels
cause multisystem diseases in children and NMDs associated with chronic progressive external
ophthalmoplegia in adults and proximal myopathy [76,79]. Other NMDs with mtDNA deletions are
sporadic inclusion body myositis (sIBM) (reported in 67% of sIBM patients) [108,109] and giant axonal
neuropathy (GAN). These deletions are generally spontaneously acquired [105], probably as accidents
during mtDNA replication in the oocyte, in the early embryo or later on, along lifetime. Some multiple
large mtDNA deletions are inherited, as they are caused by mutations in nuclear genes involved in
mtDNA replication, nucleotide synthesis or transport [92]. Spontaneous mtDNA deletions appear
to accumulate with time, and may increase the likelihood that tissue function will be impaired with
time [7].
Above all, mtDNA variants (mutations and deletions) have a broad range of impact, from the ones
that are causal of monogenic disorders to those that are a risky allele for complex diseases, in which
clinical penetrance also depend on environmental factors. For example, de novo mtDNA monogenic
mutations m.3243A > G and m.8344A > G trigger MELAS and MERRF, respectively, and can arise
spontaneously, because of replication errors. Another high impact variant is a large 4,977-bp deletion
of mtDNA, the most common cause of Kearns–Sayre syndrome. These mutations usually occur de
novo within two or three human generations and, for deletions, tend to affect only one generation [104].
In all cases, the specific mutation, the level of heteroplasmy, the threshold effect that determines the
level of phenotypic penetrance and which tissues are affected, directly determine the inheritance of the
disease and the onset and progression of these disorders.
2.2. Mitochondrial Respiratory Chain (MRC)
The MRC contains five multimeric enzymatic complexes. Complexes I–IV oxidize and transfer
their electrons, in the form of hydrogen ions, to the next complex. Once in complex IV, electrons are
transferred to molecular oxygen, producing water [7,95]. Complex V generates ATP from adenosine
diphosphate (ADP) using the transmembrane electrical potential generated by proton translocation
along the MRC [14]. This production of ATP from the reduction of oxygen, known as mitochondrial
coupling, is what generates the energy needed for cellular function [110]. In parallel, MRC generates
ROS as a subproduct of oxygen metabolism, especially in case of disease. Mutations in mtDNA can
trigger the impairment of MRC, affecting energy production and cellular dysfunction [111], observed
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in some NMDs and mitochondrial diseases [112]. mtDNA mutates more than ten times faster than
nuclear DNA, and this high mutation rate in mtDNA is based on the proximity of mtDNA to the
inner mitochondrial membrane, where ROS are generated as by-products of MRC chain, coupled
with a lack of histones and efficient DNA repair mechanisms. In addition, mtDNA has low number
of noncoding regions between genes, leading to random mutations that impact coding sequences of
genes responsible of MRC.
In particular, most of the muscular dystrophies (MD) have some MRC complexes with impaired
or decreased function (Table 1): complex I in Becker MD (BMD), complexes III and IV in DMD,
and complexes I and V in oculopharyngeal (OPMD) and in distal MD (DD). Other NMDs with MRC
alterations are myofibrillar myopathies (complexes I and IV) (Table 2), ALS (CIV subunit I) (Table 3),
SMA (complexes I and IV) (Table 3), GAN (complexes I and IV) (Table 4), and sIBM (complex IV) [108].
Impaired MRC function promotes mitochondrial dysfunction, eventually leading to progressive
weakness and muscle wasting.
To understand the extent of the how MRC dysfunction affects the progression of a NMDs or vice
versa, here we present the case of hypothyroid myopathy (endocrine myopathy, Table 2) and ALS
(motor neuron diseases, Table 3).
In hypothyroid myopathy, there is an abnormal activity of the thyroid gland, leading to reduced
hormone levels. Thyroid hormones affect skeletal muscle through T3 receptors, located on the
mitochondrial membrane of skeletal muscle fibers [113,114]. This MRC-thyroid hormones connection is
mediated by several molecular mechanisms that include both direct and indirect effects on mitochondrial
structure, function, and biogenesis. One effect in hypothyroid myopathy is a reduced mitochondrial
oxidative metabolism, due to decreased hormonal levels and a reduced amount and activity of complex
IV (cytochrome c oxidase negative fibers (or COX-)). In addition, T3 receptors, together with the
thyroid hormone receptor, increase the expression of some nuclear-encoded respiratory genes, such as
cytochrome c1 and b-F1- ATPase subunit genes [38].
Regarding ALS, ALS-associated P525L mutant interacts with ATP synthase complex subunit
TP5B, disrupting the formation of ATP synthase complex, thus inhibiting the production of ATP [115].
Both are examples of the complex and intricated pathways governing NMDs in which mitochondria,
and herein explained, MRC, play a role.
2.3. Mitochondrial Quality Control
2.3.1. Mitochondrial Biogenesis
Mitochondrial biogenesis increases the number of mitochondria, what can lead to a higher energy
supply and survival of cells; or if mutated mtDNA expands to higher levels, low energy supply,
and cell death. Both outcomes depend on random clonal expansion of mitochondria [103]. Although
mitochondrial biogenesis is energy-consuming, it helps to increase energy production and often restores
mitochondrial function. Mitochondrial biogenesis can react to many external stimuli, such as exercise,
hormones, and possibly dietary restriction, in addition to mitochondrial dysfunction [92]. In the case of
mitochondrial dysfunction, coordination between mitochondrial synthesis (mitochondrial biogenesis)
and degradation (mitophagy) regulates mitochondrial content, quality, and function.
To initiate mitochondrial biogenesis, synthesis of more MRC complexes is required.
MRC components are both encoded in nuclear and mtDNA, although their transcripts are not
synthesized simultaneously. Cytosolic translation unidirectionally controls mitochondrial translation,
both orchestrated by the nuclear genome. The nuclear genes coding for the MRC are rapidly induced
under nutrient shift, whereas mitochondrial genes coding for the MRC are induced more slowly.
Mitochondrial MRC’s slow kinetics may underlie the lack of environment-responsive mitochondrial
transcription factors. Instead of transcription factors, mitochondria contain mRNA-specific translational
activators, involved in initiation, elongation, and feedback control of MRC complexes assembly [102].
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If mitochondrial biogenesis is disrupted, it may result in mitochondrial dysfunction and
loss of respiratory capacity [103], observed in patients with mitochondrial diseases. However,
excessive mitochondrial biogenesis can also be a sign of disease. In fact, in the muscle of patients
with mitochondrial disease, mitochondrial biogenesis generates the so-called ragged-red fibers
(RRF), an increase in the number of mitochondria surrounding muscle fibers aimed to compensate
mitochondrial dysfunction (Figure 2). RRF typically loss COX activity (partially encoded in
the mitochondrial genome) and increase complex II function (succinate dehydrogenase, SDH,
entirely encoded in the nuclear genome). Thus, RRF mainly accumulate abnormal proliferated
mitochondria [94].
Alterations in some pathways may trigger accumulation of mitochondria in RRF (e.g., changes
in mitochondrial protein synthesis). In addition, RRF usually contain a higher amount of mutant
mtDNA genomes than non-RRF. Overall, RRF are a tag of defective oxidative phosphorylation in the
affected muscle fibers [7]. In fact, RRF are found in many NMDs like limb-girdle MD (LGMD), sIBM,
myofibrillar myopathies, myasthenia gravis, ALS, and mitochondrial myopathies (Tables 1–4).
2.3.2. Mitochondrial Dynamics
Mitochondria are highly dynamic organelles that continuously fuse, divide, and move,
and mitochondrial function is controlled and maintained by these morphologic changes. Mitochondrial
fission is mainly mediated by dynamin-related guanosine triphosphatase (GTPase) protein 1 (Drp1);
while in mitochondrial fusion, the outer and inner mitochondrial membranes primarily fuse mediated
by dynamin-related GTPases mitofusin (Mfn 1 and 2) and optic atrophy 1 (OPA1), respectively [103].
The most direct consequence of mitochondrial division and fusion is the change in size of the
mitochondria [105]. Interestingly, these processes promote the exchange of genetic and structural
material among participant mitochondria, thus enabling the renewal of damaged components, or its
expansion throughout the mitochondrial net (Figure 2). However, mitochondria can also increase in
number when there are the specific requirements.
When mitochondria are damaged, they undergo changes in mitochondrial membrane potential
(MMP) causing depolarization. Altered MMP can also impact the mitochondrial fission/fusion
machinery and thereby mitochondrial morphology. Mitochondrial fission generates fragmented
mitochondria with increased ROS production [106], which may help in the separation of dysfunctional
mitochondria from healthy mitochondria and is a prerequisite for mitochondrial degradation (in
a process called mitophagy) [107]. The detrimental effect of mitochondrial fission is the release of
cytochrome c from mitochondria, which could activate apoptosis signaling through activation of
Bax/Bak pore [103]. Apoptotic cell death may be an important mediator of nervous system injury
in the mitochondrial encephalomyopathies [7]. Other NMD with increased apoptosis are OPMD,
spinal-bulbar muscular atrophy (SBMA), and ion channel diseases. Defects in ion channel diseases may
directly reduce MMP and delay repolarization, affecting the modulation of cell survival and increasing
cell apoptosis.
Mitochondrial dynamics is also implicated in the pathogenesis of NMDs like inherited peripheral
neuropathy, GAN [76], infantile-onset encephalopathy [116], autosomal dominant optic atrophy [101],
and CMT2A [74]. The last three are characterized by mutations involving mitochondrial fusion
regulatory genes, OPA1 and MFN2, respectively [117]. Some mutations in mitochondrial dynamics
genes can trigger severe effects or even death. An example is a lethal dominant negative allele of DRP1
that affects mitochondrial and peroxisomes fission in newborns and triggers abnormalities in brain
development and optic atrophy [118].
Mitochondrial dynamics have also been thoroughly studied in ALS. As mutations in several
genes are responsible of ALS, depending on the gene mutated, fusion or fission of mitochondria
are enhanced. For example, TDP-43 mutations enhance Mitochondrial fission 1 protein (Fis 1)
expression, which increases DRP1 recruitment, leading to higher mitochondrial fission, and a
fragmented morphology of mitochondria. In ALS caused by SOD1, increased DRP1 and reduced
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Mfn1/Opa1 lead to higher level of mitochondrial fission and a fragmented mitochondrial network;
while in ALS related to C9ORF72 mutation, higher Mfn1 levels triggered increased mitochondrial
fusion and an elongated morphology [119]. Thus, the deregulation of mitochondrial dynamics is
frequently associated to NMDs and its proper function protects and counteracts the progression of
some NMDs.
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Figure 2. Schematic view of the mechanistic model of mitochondrial-related pathways in a cell. 1. MRC
generates ATP in the inner mitochondrial membrane. In this process, also ROS are produced. 2. In case of
excessive ROS levels, mitochondrial membrane potential decreases, allowing MPTP to open and release
DAMPs (mtDNA, cardiolipin, ceramides) to the cytosol. These DAMPs can trigger an inflammatory
response. In this scheme, the inflammatory cascade represented is the one activated by mtDNA. mtDNA
activates cGAS in cytosol, that eventually induces the expression of interferon-related genes (IRF3/IRF7).
In parallel, mtDNA activates TLR9, which activates NF-kB, and thus, NLRP3 inflammasome, expression
of pro-inflammatory cytokines, and among them, IL-1 response. 3. Increased ROS levels can result from
MRC dysfunction. To compensate dysfunctional mitochondria, mitochondrial biogenesis increases the
number of mitochondria in a cell. Excessive mitochondria around muscle cells form RRF. 4. Excessive
ROS, RRF, inflammation, and ER stress damage mitochondria, which alterations are sensed by autophagy
and mitophagy. Autophagy and mitophagy remove damaged mitochondria, and consequently stop
the inflammatory response, supporting repair mechanisms in the cell. If autophagy and mitophagy are
altered, mitochondria cannot be recycled, leading t apoptosis. Abbreviations: MRC: mitochondrial
r spiratory chain; ROS: re ctive ox ge species; MPTP: mitochondrial perme bility transition pore;
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2.3.3. Autophagy and Mitophagy
Lysosomes were discovered in 1955 [109], and soon was observed that cytoplasmic components
could be located in lysosomes [120]. This was the basis for De Duve (1963) to coin the
term autophagy [121]. Autophagy is a lysosomal degradation process characterized by the
formation of double-membrane autophagosomes from cytoplasmic material and damaged organelles.
Autophagosomes fuse with lysosomes to degrade their content by acidic hydrolases. Autophagic
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degradation generates amino acids and fatty acids for protein synthesis or oxidation in the MRC to
produce ATP for cell survival under starvation conditions. Other functions of autophagy include
removal of damaged organelles and protein aggregates, control of cellular biomass and elimination of
intracellular pathogens [92]. There are three subtypes of autophagy: macroautophagy, microautophagy,
and chaperone-mediated autophagy, divided according to the mechanism used to send intracellular
material to be degraded in the lysosomes and the kind of cargo for degradation.
Briefly, mitophagy—the specific autophagy of mitochondria—initiates with the recognition of
damaged mitochondria by the E3-ubiquitin ligase Parkin, which decorates the outer mitochondrial
membrane proteins with poly-Ub chains [122]. p62 binds polyubiquitinated proteins and damaged
organelles and target them to autophagosomal clearance via its ubiquitin association domain (UBA)
and LC3 binding motif (LIR), respectively [123]. Absence of specific mitophagy proteins can
block autophagosomal or lysosomal clearance leading to an accumulation of damaged proteins
and dysfunctional organelles in autophagosomes [124,125].
Mitophagy can occur under several circumstances: metabolic alterations (starvation, particularly),
differentiation of some cell types (requiring mitochondrial clearance), and selective targeting and
removal of dysfunctional mitochondria [126]. Mitophagy of dysfunctional mitochondria is also called
PTEN-induced putative kinase 1 (PINK1)-Parkin-mediated mitochondrial quality-control system [92],
since both PTEN and PINK1 are among the main effectors of mitophagy.
The extent of mitophagy varies in different tissues. For instance, heart, skeletal muscle, nervous
system, hepatic and renal tissue have higher mitophagy than thymus and spleen [127]. Defects
in mitophagy can lead to accumulation of dysfunctional mitochondria and increased levels of
mitochondrial ROS and damage-associated molecular pattern (DAMPs), which are self-molecules that
resemble pathogenic ones and can trigger an inflammatory response (Figure 2). Both mitochondrial
ROS and DAMPs can initiate an inflammatory response [128]. In addition, impaired mitophagy
has been linked with aging, metabolic disorders, cancer, senescence, inflammation, and genomic
instability [107]. Regarding NMDs, impaired autophagy has been revealed in congenital MD (CMD),
endocrine myopathies, inflammatory myopathies, myofibrillar myopathy and congenital myasthenic
syndromes, among others.
In CMD linked to collagen VI deficiency, impaired autophagy is responsible for spontaneous
apoptosis, dysfunctional mitochondria and myofibers degeneration. Defective autophagy causes
accumulation of abnormal organelles and apoptotic degeneration of muscle fibers. Accumulation
of defective mitochondria increases oxidative stress and ROS production, which also contribute to
increase apoptosis. The cause of defective autophagy in CMD is a reduced protein amount of beclin-1
and Bnip3, what leads to a defective activation of the autophagy process [15].
As mitophagy protects from the accumulation of defective mitochondria and ROS overproduction,
this process is frequently impaired in NMDs affecting both nerve and muscle function.
2.4. Mitochondrial ROS and ER Stress
ROS comprises superoxide anion (O2•−), hydrogen peroxide (H2O2), hydroxyl radical (OH•),
peroxyl radical (ROO•), and nitric oxide (NO•). Although mitochondrial oxidative metabolism is a major
source of ROS in many cell types, outside mitochondria there are other enzymes associated with ROS
production, like NADPH oxidase, neural nitric oxide synthase, and monoamine oxidase [129]. A balance
between oxidative species and antioxidant defense mechanisms is required for cell homeostasis [130].
Briefly, the antioxidant response is mediated by enzymes responsible for metabolizing or neutralizing
ROS, such as catalase, glutathione peroxidase, or superoxide dismutase (SODs) [131].
The high proportion of ROS generation in MRC is due to the transfer of electrons in the
inner mitochondrial membrane until they encounter oxygen, when electrons are converted in water.
Under hypoxia or pathologic conditions this process is not completed, resulting in an increase of
superoxide anions [131]. For example, mutation in SOD2, an antioxidant enzyme encoded in the
mitochondrial genome, triggers the development of CMT, a NMD [132]. Mutations in SOD1 gene are
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found in ALS. SOD1 encodes the Cu-Zn superoxide dismutase, one of three proteins involved in the
conversion of free superoxide radicals to molecular oxygen and hydrogen peroxide. Mutations in the
SOD1 gene are found in 10–20% of familial ALS cases and 1–5% of sporadic ALS cases globally [133];
so far, more than 170 mutations of the SOD1 gene are known in ALS [119].
Other NMDs in which high ROS levels are not compensated and cells hold excessive oxidative
stress are BMD, DMD, FSHD, ALS, SBMA, mitochondrial myopathies, and FA.
When overproduction of ROS cannot be compensated by antioxidant defenses or mitophagy,
ER receives ROS signals through MAMs, which may eventually activate cell stress responses to
compensate and overcome this adverse situation [134].
ER is the main organelle in charge of protein biosynthesis and folding and one of the main cell
sensors to stress insults. Alterations of the ER redox status can negatively affect protein folding and
result in ER stress. ER stress occurs when the rate at which new protein entering the ER exceeds its
folding capacity, which can lead to the activation of three transmembrane proteins: inositol-requiring
enzyme 1α (IRE1α), PKR-like ER kinase (PERK), and the activation transcription factor 6 (ATF6),
which altogether trigger a UPR [134]. The UPR is comprised of a series of transcriptional, translational,
and post-translational processes that can lower the rate of protein synthesis and increase the protein
folding capacity of the ER machinery. This results in an increase of misfolded protein elimination,
and escalating the size of the ER compartment thereby reducing the ER stress [98]. Usually, transient
ER stress can be overcome by UPR, but if the damaging stimulus persists, inflammatory response
genes are activated [131].
ER-mitochondria crosstalk is involved in several pathways including cell proliferation, apoptosis,
autophagy, lipid metabolism, Ca2+ signaling, UPR, inflammation, and bioenergetics. Alterations in this
ER-mitochondria crosstalk are associated with multiple diseases, like motor neuron diseases, myotonic
dystrophy, OPMD, endocrine myopathies, myofibrillar myopathies, SBMA, CMT, and mitochondrial
myopathies. In ALS, over expression of both wild-type and mutated TDP-43 leads to a decrease in
ER-mitochondria physical and functional coupling, affecting Ca2+ regulation. Ca2+ dysregulation is
considered to be a primary cause of motor neuron death in ALS [135]. Ca2+ is responsible for the link
between metabolic impairment and MAMs interaction. This is seen in cancer cells, which are able to
remodel their intracellular Ca2+ signaling, enhancing their survival and proliferation. Modulation of
ER-mitochondrial Ca2+ crosstalk favors resistance to apoptosis [136].
In addition to triggering ER stress, if ROS damage overwhelms these repair mechanisms,
MMP may decrease, thus potentially leading to the increase in the permeability of mitochondrial
membranes. Higher permeability in mitochondrial membrane can activate the mitochondrial
permeability transition pore (MPTP) and thus, the release of DAMPs to the cytosol (mtDNA), ceramides,
formaldehyde) [137,138]. MPTP and ROS can also promote the activation of mitochondrial fission and
mitophagy to eliminate damaged mitochondria (Figure 2). In mitochondrial fission, MAMs signal the
ER tubules to encircle mitochondria and tag the sites for mitochondrial division [139]. Accordingly
to mitochondrial implication in NMDs, dysregulation of MPTP opening and defective autophagy
have been associated with muscular dystrophies, like collagen VI myopathies (CMD), BMD, DMD,
LGMD, and DD [14,15] and, remarkably, most of NMDs show some level of deregulation in most of
these pathways.
2.5. Mitochondrially Induced Inflammatory Response
Inflammatory responses recognize pathogen-associated molecular patterns (PAMPs), derived
from infection, through a variety of receptors. However, because of the bacterial origin of mitochondria,
their proteins are structurally similar to those in bacteria and enable their recognition by the same
receptors of the immune system, reinforcing the notion of mitochondria as hubs of immunity [140].
Thus, mitochondrial DAMPs can also trigger an inflammatory response [128]. DAMPs include proteins
and peptides, such as N-formyl peptides and TFAM, as well as lipids, and metabolites such as
cardiolipin, succinate and ATP, and mtDNA [139].
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2.5.1. Implication of mtDNA in Inflammation
In particular, mtDNA is recognized by multiple innate immune receptors: cytosolic cyclic
GMP-AMP synthase (cGAS), endosomal Toll-like receptor 9 (TLR9), and NOD, LRR, and Pyrin
domain-containing protein 3 (NLRP3) [140]. Here we briefly remark the main effects of these innate
immune responses.
Cytosolic mtDNA enhances cytosolic antiviral signaling and expression of interferon-stimulated
genes (IRF3/IRF7), which results in the activation of cGAS DNA sensor and STING-IRF3-dependent
signaling [141]. These pathways activate transcription factors NF- kB and IRF3 through the kinases
IKK and TBK1, respectively. MtDNA stress triggered by TFAM deficiency has been reported to release
mtDNA to the cytosol [101].
TLR9 is a nucleic acid sensor that binds to unmethylated CpG DNA, like mtDNA. In basal
conditions, TLR9 is located in the ER, but when it is stimulated, TLR9 translocates to the membrane of
endosomes or lysosomes, where it binds to ligands and triggers cell inflammation [140].
TLR9 interaction with mtDNA occurs in the endolysosomal compartment and activates the
myeloid differentiation primary response protein 88 (MyD88), which induces a number of kinases
and transcriptional factors, namely mitogen-activated protein kinases (MAPK) [101]. MAPK leads to
nuclear factor-kB (NF-κB) and IRF7 activation to enhance pro-inflammatory and interferon type I (IFN-1)
responses, respectively [89]. NF-kB signaling increases the expression of other pro-inflammatory
cytokines such as tumor necrosis factor-a (TNF-a), interleukin (IL)-6, IL-1b [128]. Furthermore,
TLR9 senses incomplete digestion in lysosomes of damaged mitochondria, because of impaired
mitophagy, without the mtDNA release to cytosol.
The activation of the inflammasome NLRP3 involves two sequential signals. The inflammasome
priming and assembly signal is induced by NF-κB, which acts downstream of TLRs and other
immune receptors [142]. NF-kB activates the expression of inflammasome components and inactive
forms of the cytokines, including pro-IL-1b. When active, NLRP3 inflammasome activates caspase-1,
which processes pro-IL-1β and pro-IL-18 [100,143]. DAMPs directly activate NLRP3 inflammasome as
well. Mitochondria are suggested to regulate the activity of the NLRP3 inflammasome complex, by:
activating mitophagy (reduces inflammation by clearing mitochondrial-bound NLRP3 complexes) and
releasing mitochondrial ROS (amplifies inflammasome immunogenic signal) [140].
In normal conditions, NLRP3 protein is located on the ER. Under oxidative stress and in response
to inflammation, NLRP3 can be translocated to MAMs. MAMs transmit danger signals through
physical interaction, promoting coordinated responses to oxidative stress, such as triggering mitophagy
to remove damaged mitochondria [131].
Altogether, mitochondria-induced inflammation usually is initiated by mitochondrial ROS,
which can cause the activation of MAPKs by inhibiting MAPK phosphatase. Activated MAPK may
aid in the production of IL-6 and TNF. Mitochondrial ROS accumulation can also activate NLRP3
inflammasome, which promotes the maturation of IL-1β and IL-18. mtDNA accumulation in the
cytosol can interact with TLR-9 (in lysosomes) to induce inflammatory responses (e.g., in autosomal
dominant optic atrophy [101]. This pathologic feature has been described in sIBM and in LMNA-related
NMDs (CMD, Emery-Dreifuss MD, LGMD, CMT, etc.)) [144]. Further, cytosolic mtDNA can activate
cGAS-STING to induce IFN-1 or the NLRP3 inflammasome which can induce the maturation/secretion
of pro-inflammatory cytokines [101]. Thus, mtDNA can activate major innate immune responses by
acting as a DAMP from the mitochondria. Overall, mtDNA is released from mitochondria to the
cytosol, where it is recognized by immune receptors, which trigger a signaling cascade that leads to
the production of cytokines or transcription of inflammatory genes in the nucleus (Figure 2) [143].
This close association between mitochondria and inflammation triggered from affected cells, explains
why NMDs are usually associated with inflammatory effects.
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2.5.2. Implication of Mitochondrial ROS in Inflammation
Regarding mitochondrial ROS, they are sensed by mitochondrial antiviral signaling protein
(MAVS), key in viral RNA infections. MAVS can activate pathways that regulate NF-kB and IRF3/IRF7
to induce gene expression [145]. It also can interact with the outer mitochondrial membrane,
where mitochondrial ROS can trigger MAVS oligomerization, promoting IFN-1 production. In addition,
MAVS can associate with NLRP3 and triggers its oligomerization, leading to caspase-1 activation [146].
NLRP3 is activated by mitochondrial ROS but also by cardiolipin, an inner mitochondrial
membrane lipid. Cardiolipin translocates to the outer mitochondrial membrane after mitochondrial
membrane depolarization, where it can recruit NLRP3. Cardiolipin-NLRP3 interaction suggests the
role of mitochondria as a hub for the activation of innate immunity [143].
Similar to MAVS, NLRP3 also responds to mitochondrial ROS and can cause mitochondrial
damage that promotes the generation of additional ROS. NLRP3 drives the production of IL-1β,
IL-18, and pyroptosis. mtDNA can also activate NLRP3, and is also sensed by TLR9, which leads to
immune and inflammatory gene expression. Mitochondria are therefore critical for signaling by three
major innate immune pathways: RIG-I/MAVS, NLRP3, and TLR9 [143]. All these pathways rely on
mitochondria-inflammatory response and, consequently, are altered in numerous NMDs.
2.5.3. Feedback Regulation of the Mitochondrial Inflammatory Response
NF-kB has a role as a pro-inflammatory and anti-inflammatory transcription factor in
mitochondrial-induced inflammation. NF-kB anti-inflammatory functions prevent premature and
excessive NLRP3-inflammasome activation, avoiding chronic inflammatory disease and inflammation
caused by cell and tissue stress [147]. Self-limiting inflammation is also important for maintaining
homeostasis, tissue repair, and regeneration, which restores integrity of epithelial barriers and thereby
attenuates PAMP and DAMP availability [100].
Autophagy is the mechanism underlying NF-kB-mediated inhibition of NLRP3 inflammasome.
After inducing the expression of pro-inflammatory cytokines and NLRP3, NF-kB is able to switch
the initial pro-inflammatory to an anti-inflammatory state to avoid excessive inflammation. Thus,
NF-kB induces the expression of p62, which eliminates NLRP3 by mitophagy [138]. Therefore,
the “NF-kB-p62/SQSTM1-mitophagy” pathway provides an essential regulatory loop through which
NF-kB orchestrates a reparative inflammatory response and prevents excessive collateral damage [100].
Dysregulation of the NLRP3-inflammasome is frequently associated with diverse inflammatory,
metabolic, and malignant diseases, including gouty arthritis, Alzheimer’s disease, obesity, type II
diabetes, and colorectal cancer [148]. Other NMDs with increased inflammation are ALS (with aberrant
activation of NF-kB) [17], muscular dystrophies (like BMD and DMD), and inflammatory myopathies.
Therefore, proper control of NLRP3-inflammasome activity and overall inflammatory cascade are
critical for preventing disease development.
The aging process itself is linked to elevated low-grade inflammation or para-inflammation,
characterized by constitutive production of low amounts of IL-1b, TNF, and IL-6.
The NLRP3-inflammasome activation and insufficient mitophagy link accumulation of damaged
mitochondria to the para-inflammatory state. Normal, healthy aging may be compromised and greatly
enhanced by accumulation of somatically mutated mitochondria, which are more likely to release
mitochondrial ROS and fragmented mtDNA that act as direct NLRP3-inflammasome activators [100].
This explains why most of NMDs arise hand by hand to aging processes.
3. Treatment Strategies in NMDs
As stated before, mitochondria play a key role in the early process of nerve and muscle degeneration
and affects the progression of NMDs. Although current understanding of mitochondrial dysfunction
in NMD is still evolving, there are some potential therapeutic strategies that tackle mitochondrial
deregulated pathways.
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The number of NMDs for which treatments are available is limited. This scarcity of therapeutic
options lays on the rarity and diversity of NMDs, the complexity of their genetic inheritance,
the abundance and distribution of muscle tissue, and low treatment efficacy [14]. The rarity of NMDs
limits the available patients for recruitment for clinical trials, which highly depends on the quality and
reliability of data obtained in cell and animal experiments [149].
Despite there is no cure for most NMDs, some can be effectively managed and treated.
Some common interventions include drug therapy, surgery, or patient support groups, to improve
physical and psychological wellbeing of NMD patients [6]. Innovative breakthroughs are approaching
owing to antisense oligonucleotides (ASO) and gene replacement therapies, currently under
development. Here we summarize the main points of different treatment strategies, most of them
posing supportive pharmacologic options aimed not to cure but to slow down disease progression.
Drug therapy in NMDs comprises a wide range of treatments. Immunosuppressive drugs are
widely used to treat certain muscle, nerve, and NMJ diseases. Anticonvulsants and antidepressants
might aid in treating the pain of neuropathy [6]. More specifically, senolytic drugs (e.g., resveratrol)
help to remove senescent cells to reduce the overall pro-inflammatory profile, although inflammation
differs among tissues and makes it difficult to only target senescent cells [82]. Interestingly, resveratrol
has been associated to promote mitochondrial health and renewal through different mechanisms [150].
Other treatment options are being developed to specifically target mitochondria. For example
metformin, used as an anticancer drug, increases the activation of AMPK, favoring autophagy of
damaged mitochondria (e.g., in mitochondrial diseases and DMD); caloric restriction, which reduces
ROS production and thus, DNA damage (in collagen VI myopathies); and mitohormesis, based in
inducing mild mitochondrial stress during life to induce an antioxidant response (e.g., by vitamin E).
Some dietary supplements boost mitochondrial capacity like niacin (vitamin B3) in mitochondrial
myopathy; epicatechin in BMD, or triheptanoin, CoQ10 and tocotrienols in ALS [151].
Moreover, exercise has shown to induce autophagy to overcome sarcopenia (e.g., in metabolic
myopathies) [152]. In young and old mice, exercise training has even promoted biogenesis of
mitochondria and mitochondrial autophagy to reduce the expression of proinflammatory cytokines by
up to 49% [82]. Unfortunately, exercise is not always possible in patients affected by NMDs.
Other mitochondrial pathways that could be tackled therapeutically are dysregulation of MPTP
opening, mitochondrial fission, and ER stress. MPTP modifiers (e.g., CsA, cyclophilin D inhibitors)
might potentially aid in many NMDs [14]. Targeting mitochondrial fission is based on its direct relation
to apoptosis, thus reducing fission might reduce cell death. Treating ER stress could be relevant in many
NMD and other proteinopathies [30]. Currently, these therapeutic approaches are under development.
In addition to drug therapy, some NMDs benefit from surgery. Depending on the NMD,
patients may receive neurological, thoracic, orthopedic, or other surgeries. Physical, occupational,
or rehabilitation therapies may help before or after these interventions [6].
Recently, other approaches more related to personalized medicine are being developed or even
in the market, like ASO and gene therapy. ASOs are short, synthetic single-stranded nucleic acids
that bind targeted RNAs sequences to promote their degradation or modify splicing by impeding
the binding of RNA splicing factors [153]. This approach has been developed in SMA and DMD and
approved by FDA. In SMA, an ASO that switches the splicing to include an exon in the pre-mRNA of
SMN2 gene has become the first treatment for SMA approved by FDA, commercialized by Biogen
(MA, USA) under the name Nusinersen [67].
In DMD, an exon skipping ASO called Eteplirsen is also approved and commercially available.
In this case, exon-skipping of damaged dystrophin in DMD generates a shortened but still functional
version of dystrophin [154]. Other NMDs like LGMD could benefit from ASO exon skipping,
by restoring the disrupted reading frame of the SGCG gene [5,27].
Apart from ASOs, gene replacement therapies are under development. In SMA, there is a gene
replacement therapy available for patients younger than 2 years old. In this case, SMN1 gene cDNA
is packaged in an adeno-associated virus 9 vector (AAV9), which are non-pathogenic, delivered
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intravenously and can cross the blood brain barrier to transduce neurons [155]. Once inside neurons,
SMN1 cDNA constitutively expresses, with long-term expression in differentiated cells after a single
dose, but not in mitotically active cells. This drug has shown efficacy in infantile SMA patients
and is commercialized by Avexis under the name Zolgensma [67,156]. Other gene therapies using
CRISPR/Cas-mediated approaches in NMD have shown efficacy in models of DMD, CMD, LGMD,
DM1, and FSHD [157], becoming promising therapeutic approaches for further transference into
clinical settings.
Altogether, currently there are nearly 200 potential therapies under development for NMD
(in preclinical and clinical stages), mainly targeting ALS, SMA, and DMD [158]. Around 43% are
small molecules (targeting receptor modulation, epigenetic reprogramming, redox metabolism, etc.),
14% gene therapy and 9% antisense oligonucleotides (ASOs) [159]. This shows that personalized
medicine is increasingly offering new treatments for rare diseases, like NMDs. Indeed, the number of
molecules in clinical trials for NMD has sharply increased in the last 5 years [158]. This proves NMD
therapies are becoming a highly dynamic and potentially achieving field [8].
Notably, treatments not only focus in improving physical health of NMD patients, but also patients
and families receive education and counselling to check their wellbeing. This may include getting
involved in support groups or genetic counsellors (e.g., physical therapists, nutritionists). Patient’s
associations are highly interested in creating support groups and analyze the quality of life of NMD
patients and carers. One ongoing project, promoted by Share4Rare and released in the beginning of
2020, consists in a study called “Understanding how neuromuscular diseases impact learning and
working opportunities for patients and carers.” They claim that patients with rare NMDs are a scattered
community, often dispersed, and poorly represented. Even with the increased interest in developing
research and potential therapeutic options in clinical trials in the last 10 years, little is known about
the impact on quality of life of NMDs. With this study, they focus on understanding the psychosocial
impact of NMD on patients, families, and caregivers [160].
4. Discussion
Despite we must acknowledge the impossibility of summarizing all previous knowledge in the
current review, the present revision aimed to outline the state-of-the-art in the main etiologies of NMDs
related to mitochondrial metabolism. The role of oxidative stress, mitochondrial biogenesis, autophagy,
and inflammation related to mitochondria have been thoroughly described and linked to the affected
NMDs (Figure 2). Overall, mitochondrial defects play a key role in the early process of neuronal and
muscle degeneration and further affects the progression of NMDs.
NMDs can appear as a result of damage in nerve, muscle, or both tissues. In fact, the classification
of NMDs include seven groups, two of them with primary muscle affection (MD and myopathies
other than dystrophies), three of them with primary nerve dysfunction (NMJ diseases, peripheral
nerve diseases and motor neuron diseases) and last two with both tissues affected (mitochondrial
diseases and ion channel diseases). More attention should be focused on identifying prognostic and
diagnostic biomarkers that target a specific pathway to accurately diagnose every NMD and control
its progression.
Despite the number of treatments for NMD is still limited, some experimental treatments are
currently under development to tackle mitochondrial deregulated pathways in NMDs. Current
studies and clinical trials in many disabling NMDs aim to improve the wellbeing of patients and their
families, but deep understanding of mitochondrial dysfunction in NMD will be essential to validate
and establish further therapeutic targets.
The preclinical and clinical research advances in NMDs in the last years have been astounding.
Better cell and animal models have helped in the characterization of many NMDs. Furthermore,
the broad diversity and rarity of these diseases have revealed the importance of carefully studying
every NMD history and progression. This more accurate approach is translating to more personalized
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treatments, as seen with new ASOs and gene therapies recently released to the market, and will
eventually lead to a higher success rate in clinical trials for these disabling diseases.
5. Conclusions
• NMDs have a direct or indirect influence of mitochondria in their etiology. Mitochondrial genetic
defects directly affect nerves and muscles in NMDs; but when there is an alternative cause of
disease, unproper mitochondrial function can limit energetic supply of compensatory mechanisms,
thus indirectly conditioning the progression of disease.
• Defects in oxidative metabolism can lead to accumulation of ROS, potentially affecting the ER and
triggering inflammation, which eventually may lead to cell death and tissue damage.
• To avoid cell damage and excessive oxidative stress, mitochondrial quality control processes
closely monitor changes in mitochondrial metabolism. In case of trouble, different responses arise
by the increase in the number of mitochondria (mitochondrial biogenesis), by changing their
morphology and size (mitochondrial dynamics) or recycling them (mitophagy). Most of these
processes are altered in NMDs, highlighting the relevance of mitochondria in the development
and progression of these disorders.
• Understanding nerves, muscles, and mitochondrial defects in NMDs is essential to improve
diagnosis and treatments for these major incapacitating diseases.
• Despite growing efforts to clarify the etiology of NMD, the complexity of reality is still far beyond
current knowledge and information provided in the present review, challenging new researchers
to develop novel approaches.
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